Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Summary

• On October 18, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired deferred stock units.
• The transaction involved 213.5112 deferred stock units, each representing the right to receive one share of Elanco common stock or the cash equivalent.
• The price of the derivative security was $12.97.
• Following the reported transaction, Simmons directly owns 3,906.5502 derivative securities.
• These deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and transactions of company executives. It's common for executives to receive stock-based compensation, aligning their interests with those of shareholders.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and alignment of interests.
• Employees: Informs employees about executive compensation structures.

Key Dates